Skip to main content

Articles

Page 25 of 34

  1. Synaptic dysfunction contributes to cognitive impairment in Alzheimer’s disease and may be countered by increased intake of nutrients that target brain phospholipid metabolism. In this study, we explored wheth...

    Authors: Anne Rijpma, Marinette van der Graaf, Marieke M. Lansbergen, Olga Meulenbroek, Aysun Cetinyurek-Yavuz, John W. Sijben, Arend Heerschap and Marcel G. M. Olde Rikkert
    Citation: Alzheimer's Research & Therapy 2017 9:51
  2. CAD-31 is an Alzheimer’s disease (AD) drug candidate that was selected on the basis of its ability to stimulate the replication of human embryonic stem cell-derived neural precursor cells as well as in APPswe/...

    Authors: Daniel Daugherty, Joshua Goldberg, Wolfgang Fischer, Richard Dargusch, Pamela Maher and David Schubert
    Citation: Alzheimer's Research & Therapy 2017 9:50
  3. The Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers Aβ1–42, t-tau, and p-tau181 overlap with other diseases. New tau modifications or epitopes, such as the non-phosphorylated tau fraction (p-taurel)...

    Authors: Joery Goossens, Maria Bjerke, Hanne Struyfs, Ellis Niemantsverdriet, Charisse Somers, Tobi Van den Bossche, Sara Van Mossevelde, Bart De Vil, Anne Sieben, Jean-Jacques Martin, Patrick Cras, Johan Goeman, Peter Paul De Deyn, Christine Van Broeckhoven, Julie van der Zee and Sebastiaan Engelborghs
    Citation: Alzheimer's Research & Therapy 2017 9:49
  4. This study sought to evaluate gender and APOE genotype-related differences in the concentrations of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and cerebrovascular injury across the life spa...

    Authors: Ge Li, Jane B. Shofer, Eric C. Petrie, Chang-En Yu, Charles W. Wilkinson, Dianne P. Figlewicz, Andrew Shutes-David, Jing Zhang, Thomas J. Montine, Murray A. Raskind, Joseph F. Quinn, Douglas R. Galasko and Elaine R. Peskind
    Citation: Alzheimer's Research & Therapy 2017 9:48
  5. Longitudinal studies of dementia with Lewy bodies (DLB) are rare. Clinically, DLB is usually considered to worsen into Alzheimer’s disease (AD). The aim of our study was to compare the rate of the cognitive de...

    Authors: Frédéric Blanc, Rachid Mahmoudi, Thérèse Jonveaux, Jean Galmiche, Gilles Chopard, Benjamin Cretin, Catherine Demuynck, Catherine Martin-Hunyadi, Nathalie Philippi, François Sellal, Jean-Marc Michel, Gregory Tio, Melanie Stackfleth, Pierre Vandel, Eloi Magnin, Jean-Luc Novella…
    Citation: Alzheimer's Research & Therapy 2017 9:47
  6. Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer’s disease and other tauopathies. Immunotherapy against tau has shown ...

    Authors: Sulana Schroeder, Aurelie Joly-Amado, Ahlam Soliman, Urmi Sengupta, Rakiz Kayed, Marcia N. Gordon and David Morgan
    Citation: Alzheimer's Research & Therapy 2017 9:46
  7. The original paper Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify individuals with mild cognitive impairment (MCI) or early dementia. We e...

    Authors: Douglas W. Scharre, Shu ing Chang, Haikady N. Nagaraja, Nicole E. Vrettos and Robert A. Bornstein
    Citation: Alzheimer's Research & Therapy 2017 9:44
  8. Hyperhomocysteinemia is a risk factor for cognitive decline and dementia, including Alzheimer disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid and metabolite of the methionine pathway. The in...

    Authors: Loïc Dayon, Seu Ping Guiraud, John Corthésy, Laeticia Da Silva, Eugenia Migliavacca, Domilė Tautvydaitė, Aikaterini Oikonomidi, Barbara Moullet, Hugues Henry, Sylviane Métairon, Julien Marquis, Patrick Descombes, Sebastiano Collino, François-Pierre J. Martin, Ivan Montoliu, Martin Kussmann…
    Citation: Alzheimer's Research & Therapy 2017 9:43
  9. A major challenge to our understanding of the molecular mechanisms of Alzheimer’s disease (AD) has been the lack of physiologically relevant in vitro models which capture the precise patient genome, in the cel...

    Authors: Charles Arber, Christopher Lovejoy and Selina Wray
    Citation: Alzheimer's Research & Therapy 2017 9:42
  10. β-Amyloid peptide (Aβ) oligomers are initial factors used to induce Alzheimer’s disease (AD) development, and Aβ monomers have normal physiological function. The antibodies or vaccines against Aβ monomers have...

    Authors: Shao-wei Wang, Dong-qun Liu, Ling-xiao Zhang, Mei Ji, Yang-xin Zhang, Quan-xiu Dong, Shu-ying Liu, Xi-xiu Xie and Rui-tian Liu
    Citation: Alzheimer's Research & Therapy 2017 9:41
  11. The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain patholog...

    Authors: Hugo Vanderstichele, Leentje Demeyer, Shorena Janelidze, Els Coart, Erik Stoops, Kimberley Mauroo, Victor Herbst, Cindy François and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2017 9:40
  12. Spaced retrieval training (SRT) is a nonpharmacological intervention for mild cognitive impairment (MCI) and dementia that trains the learning and retention of target information by recalling it over increasin...

    Authors: Ji Won Han, Kyung Lak Son, Hye Jin Byun, Ji Won Ko, Kayoung Kim, Jong Woo Hong, Tae Hyun Kim and Ki Woong Kim
    Citation: Alzheimer's Research & Therapy 2017 9:39
  13. Pyroglutamylation of truncated Aβ peptides, which is catalysed by enzyme glutaminyl cyclase (QC), generates pE-Aβ species with enhanced aggregation propensities and resistance to most amino-peptidases and endo...

    Authors: Claire Bridel, Torsten Hoffmann, Antje Meyer, Sisi Durieux, Marleen A. Koel-Simmelink, Matthias Orth, Philip Scheltens, Inge Lues and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2017 9:38
  14. A lot of attention has been paid to the relationship of blood pressure and dementia because epidemiological research has reported conflicting evidence. Observational data has shown that midlife hypertension is...

    Authors: Jessica Mira Gabin, Kristian Tambs, Ingvild Saltvedt, Erik Sund and Jostein Holmen
    Citation: Alzheimer's Research & Therapy 2017 9:37
  15. The complexity of medication therapy in older adults with multiple comorbidities often leads to inappropriate prescribing. Drugs with anticholinergic properties are of particular interest because many are not ...

    Authors: Daniela C. Moga, Erin L. Abner, Dorinda N. Rigsby, Lynne Eckmann, Mark Huffmyer, Richard R. Murphy, Beth B. Coy and Gregory A. Jicha
    Citation: Alzheimer's Research & Therapy 2017 9:36
  16. Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiol...

    Authors: Joshua D. Grill, Liana G. Apostolova, Szofia Bullain, Jeffrey M. Burns, Chelsea G. Cox, Malcolm Dick, Dean Hartley, Claudia Kawas, Sarah Kremen, Jennifer Lingler, Oscar L. Lopez, Mark Mapstone, Aimee Pierce, Gil Rabinovici, J. Scott Roberts, Seyed Ahmad Sajjadi…
    Citation: Alzheimer's Research & Therapy 2017 9:35
  17. Safety warnings from health authorities are currently intended to limit the use of antipsychotics (APs) in dementia-related conditions to treat neuropsychiatric symptoms, such as disturbing and/or delusional b...

    Authors: Karim Tifratene, Valeria Manera, Roxane Fabre, Auriane Gros, Susanne Thummler, Christian Pradier, Philippe Robert and Renaud David
    Citation: Alzheimer's Research & Therapy 2017 9:34
  18. The relative performance of semi-quantitative amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) markers in diagnosing Alzheimer’s disease (AD) and predicting the cognitive evolution of p...

    Authors: Fayçal Ben Bouallègue, Denis Mariano-Goulart and Pierre Payoux
    Citation: Alzheimer's Research & Therapy 2017 9:32
  19. Insulin resistance (IR) has previously been associated with an increased risk of developing Alzheimer’s disease (AD), although the relationship between IR and AD is not yet clear. Here, we examined the influen...

    Authors: Sarah Westwood, Benjamine Liu, Alison L. Baird, Sneha Anand, Alejo J. Nevado-Holgado, Danielle Newby, Maria Pikkarainen, Merja Hallikainen, Johanna Kuusisto, Johannes R. Streffer, Gerald Novak, Kaj Blennow, Ulf Andreasson, Henrik Zetterberg, Ulf Smith, Markku Laakso…
    Citation: Alzheimer's Research & Therapy 2017 9:31
  20. Aggregated amyloid-β peptide 1–42 (Aβ42), derived from the cellular amyloid precursor protein, is one of the pathological hallmarks of Alzheimer’s disease (AD). Although active immunization against Aβ42 peptid...

    Authors: Doris Lambracht-Washington, Min Fu, Pat Frost and Roger N. Rosenberg
    Citation: Alzheimer's Research & Therapy 2017 9:30
  21. Progressive supranuclear palsy (PSP) with a frontal presentation, characterized by cognitive deficits and behavioral changes, has been recognized as an early clinical picture, distinct from the classical so-ca...

    Authors: Wang Zheng Chiu, Laura Donker Kaat, Agnita J. W. Boon, Wouter Kamphorst, Axel Schleicher, Karl Zilles, John C. van Swieten and Nicola Palomero-Gallagher
    Citation: Alzheimer's Research & Therapy 2017 9:28
  22. Cognitive, behavioural, and functional assessment is crucial in longitudinal studies of neurodegenerative dementias (NDD). Central issues, such as the definition of the study population (asymptomatic, at risk,...

    Authors: Alberto Costa, Thomas Bak, Paolo Caffarra, Carlo Caltagirone, Mathieu Ceccaldi, Fabienne Collette, Sebastian Crutch, Sergio Della Sala, Jean François Démonet, Bruno Dubois, Emrah Duzel, Peter Nestor, Sokratis G. Papageorgiou, Eric Salmon, Sietske Sikkes, Pietro Tiraboschi…
    Citation: Alzheimer's Research & Therapy 2017 9:27
  23. Informal care is essential for many people with dementia (PwD), but it often results in a considerable burden for the caregiver. The perseverance time instrument integrates the aspect of perceived burden with ...

    Authors: Anke Richters, René J. F. Melis, N. Job van Exel, Marcel G. M. Olde Rikkert and Marjolein A. van der Marck
    Citation: Alzheimer's Research & Therapy 2017 9:26
  24. 18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of 18F-THK5351 retention in brain regions thought to con...

    Authors: Kok Pin Ng, Tharick A. Pascoal, Sulantha Mathotaarachchi, Joseph Therriault, Min Su Kang, Monica Shin, Marie-Christine Guiot, Qi Guo, Ryuichi Harada, Robert A. Comley, Gassan Massarweh, Jean-Paul Soucy, Nobuyuki Okamura, Serge Gauthier and Pedro Rosa-Neto
    Citation: Alzheimer's Research & Therapy 2017 9:25
  25. The incidence of Alzheimer’s disease (AD) strongly relates to advanced age and progressive deposition of cerebral amyloid-beta (Aβ), hyperphosphorylated tau, and iron. The purpose of this study was to investig...

    Authors: Frances C. Quevenco, Maria G. Preti, Jiri M. G. van Bergen, Jun Hua, Michael Wyss, Xu Li, Simon J. Schreiner, Stefanie C. Steininger, Rafael Meyer, Irene B. Meier, Adam M. Brickman, Sandra E. Leh, Anton F. Gietl, Alfred Buck, Roger M. Nitsch, Klaas P. Pruessmann…
    Citation: Alzheimer's Research & Therapy 2017 9:24
  26. The apolipoprotein E ɛ4 (APOE4) allele is the strongest genetic risk factor identified for developing Alzheimer’s disease (AD). Among brain lipids, alteration in the ω-3 polyunsaturated fatty acid docosahexaenoic...

    Authors: Hussein N. Yassine, Etienne Croteau, Varun Rawat, Joseph R. Hibbeln, Stanley I. Rapoport, Stephen C. Cunnane and John C. Umhau
    Citation: Alzheimer's Research & Therapy 2017 9:23
  27. Errorless learning (EL) is a method for optimizing learning, which uses feed-forward instructions in order to prevent people from making mistakes during the learning process. The majority of previous studies o...

    Authors: Sebastian Voigt-Radloff, Maartje M. E. de Werd, Rainer Leonhart, Danielle H. E. Boelen, Marcel G. M. Olde Rikkert, Klaus Fliessbach, Stefan Klöppel, Bernhard Heimbach, Andreas Fellgiebel, Richard Dodel, Gerhard W. Eschweiler, Lucrezia Hausner, Roy P. C. Kessels and Michael Hüll
    Citation: Alzheimer's Research & Therapy 2017 9:22
  28. Our study aimed to determine whether the consideration of socio-demographic features improves the prediction of Alzheimer’s dementia (AD) at 5 years when using the Free and Cued Selective Reminding Test (FCSRT...

    Authors: Thibault Mura, Marieta Baramova, Audrey Gabelle, Sylvaine Artero, Jean-François Dartigues, Hélène Amieva and Claudine Berr
    Citation: Alzheimer's Research & Therapy 2017 9:21
  29. Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimer’s disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks ...

    Authors: Jong-Chan Park, Sun-Ho Han, Hyun Jin Cho, Min Soo Byun, Dahyun Yi, Young Min Choe, Seokjo Kang, Eun Sun Jung, Su Jin Won, Eun Hye Kim, Yu Kyeong Kim, Dong Young Lee and Inhee Mook-Jung
    Citation: Alzheimer's Research & Therapy 2017 9:20
  30. Cortical and subcortical cognitive impairments have been found in dementia with Lewy bodies (DLB). Roughly, they comprise visuoconstructive and executive dysfunction, whereas memory would remain relatively spa...

    Authors: Jennifer Kemp, Nathalie Philippi, Clélie Phillipps, Catherine Demuynck, Timothée Albasser, Catherine Martin-Hunyadi, Catherine Schmidt-Mutter, Benjamin Cretin and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2017 9:19
  31. Accurate and timely diagnosis of Alzheimer’s disease (AD) is important for prompt initiation of treatment in patients with AD and to avoid inappropriate treatment of patients with false-positive diagnoses.

    Authors: Spencer A. W. Lee, Luciano A. Sposato, Vladimir Hachinski and Lauren E. Cipriano
    Citation: Alzheimer's Research & Therapy 2017 9:18
  32. Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive functi...

    Authors: Raphael Hesse, Ludwig Lausser, Pauline Gummert, Florian Schmid, Anke Wahler, Cathrin Schnack, Katja S. Kroker, Markus Otto, Hayrettin Tumani, Hans A. Kestler, Holger Rosenbrock and Christine A. F. von Arnim
    Citation: Alzheimer's Research & Therapy 2017 9:17
  33. The number of people living with dementia is expected to exceed 130 million by 2050, which will have serious personal, social and economic implications. Employing successful intervention and treatment strategi...

    Authors: Shea J. Andrews, Ranmalee Eramudugolla, Jorge I. Velez, Nicolas Cherbuin, Simon Easteal and Kaarin J. Anstey
    Citation: Alzheimer's Research & Therapy 2017 9:16
  34. There is little information on the application and impact of revised criteria for diagnosing dementia and mild cognitive impairment (MCI), now termed major and mild neurocognitive disorders (NCDs) in the DSM-5...

    Authors: Ranmalee Eramudugolla, Moyra E. Mortby, Perminder Sachdev, Chantal Meslin, Rajeev Kumar and Kaarin J. Anstey
    Citation: Alzheimer's Research & Therapy 2017 9:15
  35. Previously, the contribution of peripheral infection to cognitive decline was largely overlooked however, the past 15 years have established a key role for infectious pathogens in the progression of age-relate...

    Authors: Róisín M. McManus and Michael T. Heneka
    Citation: Alzheimer's Research & Therapy 2017 9:14
  36. Retinal imaging may serve as an alternative approach to monitor brain pathology in Alzheimer’s disease (AD). In this study, we investigated the association between retinal vascular and structural changes and c...

    Authors: S.Mojtaba Golzan, Kathryn Goozee, Dana Georgevsky, Alberto Avolio, Pratishtha Chatterjee, Kaikai Shen, Vivek Gupta, Roger Chung, Greg Savage, Carolyn F. Orr, Ralph N. Martins and Stuart L. Graham
    Citation: Alzheimer's Research & Therapy 2017 9:13
  37. At present, dementia has no known cure. Interventions to delay onset and reduce prevalence of the disease are therefore focused on risk factor reduction. Previous population attributable risk estimates for wes...

    Authors: Kimberly Ashby-Mitchell, Richard Burns, Jonathan Shaw and Kaarin J. Anstey
    Citation: Alzheimer's Research & Therapy 2017 9:11
  38. Despite substantial research and development investment in Alzheimer’s disease (AD), effective therapeutics remain elusive. Significant emerging evidence has linked cholesterol, β-amyloid and AD, and several s...

    Authors: Nophar Geifman, Roberta Diaz Brinton, Richard E. Kennedy, Lon S. Schneider and Atul J. Butte
    Citation: Alzheimer's Research & Therapy 2017 9:10
  39. Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer’s disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a m...

    Authors: Steinunn Thordardottir, Anne Kinhult Ståhlbom, Ove Almkvist, Håkan Thonberg, Maria Eriksdotter, Henrik Zetterberg, Kaj Blennow and Caroline Graff
    Citation: Alzheimer's Research & Therapy 2017 9:9
  40. We sought to define a cutoff for β-amyloid 1–42 in cerebrospinal fluid (CSF), a key marker for Alzheimer’s disease (AD), with data-driven Gaussian mixture modeling in a memory clinic population.

    Authors: Daniela Bertens, Betty M. Tijms, Philip Scheltens, Charlotte E. Teunissen and Pieter Jelle Visser
    Citation: Alzheimer's Research & Therapy 2017 9:8
  41. The pathophysiology of insulin resistance-induced hypertension and hyperlipidemia might entail differences in dementia risk in cases with hypertension and hyperlipidemia without prior diabetes mellitus (DM). T...

    Authors: Yen-Chun Fan, Jung-Lung Hsu, Hong-Yi Tung, Chia-Chi Chou and Chyi-Huey Bai
    Citation: Alzheimer's Research & Therapy 2017 9:7
  42. During adulthood, personality characteristics may contribute to the individual capacity to compensate the impact of developing cerebral Alzheimer’s disease (AD) pathology on cognitive impairment in later life....

    Authors: Domilė Tautvydaitė, Deepti Kukreja, Jean-Philippe Antonietti, Hugues Henry, Armin von Gunten and Julius Popp
    Citation: Alzheimer's Research & Therapy 2017 9:6
  43. Carriers of the APOE ε4 allele are at increased risk of developing Alzheimer’s disease (AD), and have been shown to have reduced cerebral metabolic rate of glucose (CMRgl) in the same brain areas frequently affec...

    Authors: Henrietta M. Nielsen, Kewei Chen, Wendy Lee, Yinghua Chen, Robert J. Bauer III, Eric Reiman, Richard Caselli and Guojun Bu
    Citation: Alzheimer's Research & Therapy 2017 9:5
  44. Amyloid precursor protein (APP) is cleaved by β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) to produce β-amyloid (Aβ), a critical pathogenic peptide in Alzheimer’s disease (AD). Aβ generation can ...

    Authors: Na-Young Kim, Mi-Hyang Cho, Se-Hoon Won, Hoe-Jin Kang, Seung-Yong Yoon and Dong-Hou Kim
    Citation: Alzheimer's Research & Therapy 2017 9:4
  45. Noninvasive and effective biomarkers for early detection of amnestic mild cognitive impairment (aMCI) before measurable changes in behavioral performance remain scarce. Cognitive event-related potentials (ERPs...

    Authors: Juan Li, Lucas S. Broster, Gregory A. Jicha, Nancy B. Munro, Frederick A. Schmitt, Erin Abner, Richard Kryscio, Charles D. Smith and Yang Jiang
    Citation: Alzheimer's Research & Therapy 2017 9:3
  46. Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positr...

    Authors: Marissa D. Zwan, Femke H. Bouwman, Elles Konijnenberg, Wiesje M. van der Flier, Adriaan A. Lammertsma, Frans R. J. Verhey, Pauline Aalten, Bart N. M. van Berckel and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2017 9:2